Chronic Graft-versus-host-disease Clinical Trial
— AGAVE-201Official title:
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy
Verified date | June 2024 |
Source | Syndax Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
Status | Active, not recruiting |
Enrollment | 241 |
Est. completion date | December 2024 |
Est. primary completion date | June 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: 1. Participants must be 2 years of age or older, at the time of signing the informed consent. 2. Participants who are allogeneic hematopoietic stem cell transplantation (HSCT) recipients with active cGVHD requiring systemic immune suppression. Active cGVHD is defined as the presence of signs and symptoms of cGVHD per 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD. 3. Participants with refractory or recurrent active cGVHD despite at least 2 lines of systemic therapy. - Refractory disease defined as meeting any of the following criteria: - The development of 1 or more new sites of disease while being treated for cGVHD. - Progression of existing sites of disease despite at least 1 month of standard or investigation therapy for cGVHD. - Participants who have not achieved a response within 3 months on their prior therapy for cGVHD and for whom the treating physician believes a new systemic therapy is required. - Recurrent cGVHD is active, symptomatic disease (after an initial response to prior therapy) as defined, based on the NIH 2014 consensus criteria, by organ-specific or global assessment or for which the physician believes that a new line of systemic therapy is required. 4. Participants may have persistent, active acute and cGVHD manifestations (overlap syndrome), as defined by 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD. 5. Karnofsky Performance Scale of =60 (if aged 16 years or older); Lansky Performance Score of =60 (if aged <16 years) 6. Adequate organ and bone marrow functions evaluated during the 14 days prior to randomization. 7. Creatinine clearance (CrCl) =30 milliliter/minute based on the Cockcroft-Gault formula in adult participants and Schwartz formula in pediatric participants. 8. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 9. Concomitant use a of systemic corticosteroid is allowed but not required. Topical and inhaled corticosteroid agents are allowed. If a participant is taking corticosteroids at study randomization, they must be on a stable dose of corticosteroids for at least 2 weeks prior to Cycle 1 Day 1. 10. Concomitant use of CNI or mammalian target of repamycin (mTOR) inhibitors (sirolimus or everolimus) is allowed but not required. 11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol. A parent/guardian should provide consent for pediatric participants unable to provide consent themselves; in addition, where applicable pediatric participants should sign their own assent form. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: 1. Has acute GVHD without manifestations of cGVHD. 2. Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening. 3. History of acute or chronic pancreatitis. 4. History of myositis. 5. History or other evidence of severe illness, uncontrolled infection or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study. 6. Participants with acquired immune deficiency syndrome (AIDS). 7. Hepatitis B (defined as hepatitis B virus [HBV] surface antigen positive and HBV core antibody positive, with positive HBV deoxyribonucleic acid [DNA], or HBV positive core antibody alone with positive HBV DNA. Hepatitis C (defined as positive hepatitis C [HCV] antibody with positive HCV ribonucleic acid [RNA]). 8. Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of randomization, unless previously treated with curative intent and approved by Sponsor's Medical Monitor (for example, completely resected basal cell or squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection). 9. Female participant who is pregnant or breastfeeding. 10. Previous exposure to CSF1-R targeted therapies. 11. Taking agents for treatment of cGVHD other than corticosteroids or either a CNI or mTOR inhibitor is prohibited. 12. For approved or commonly used agents, other than corticosteroids, CNI and mTOR inhibitor, a washout of 2 weeks or 5 half-lives, whichever is shorter, is required at study enrollment. 13. Receiving another investigational treatment within 28 days of randomization. 14. Participants should not be participating in any other interventional study. Pediatric participants are encouraged to also participate in the ongoing developmental studies of the Pediatric cGVHD Symptom Scale (PCSS). |
Country | Name | City | State |
---|---|---|---|
Australia | The Royal Children's Hospital | Parkville | Victoria |
Australia | Westmead Hospital | Westmead | |
Belgium | Universitaire Ziekenhuizen Leuven | Leuven | |
Belgium | AZ Delta | Roeselare | |
Canada | CHU Sainte-Justine | Montreal | Quebec |
Canada | McGill University Health Center - Research Institute | Montréal | Quebec |
Canada | Princess Margaret Hospital | Toronto | Ontario |
Canada | Vancouver Coastal Health Authority | Vancouver | British Columbia |
France | CHU Amiens Picardie - Hopital Sud | Amiens | Hauts-de-France |
France | CHU de Grenoble | La Tronche | Auvergne-Rhône-Alpes |
France | CHRU de Lille - Hopital Claude Huriez | Lille | Hauts-de-France |
France | CHRU de Nancy - Hôpitaux de Brabois | Nancy | |
France | CHU de Nantes - Hôtel-Dieu | Nantes | |
France | Hopital Pitie Salpetriere | Paris | |
France | Hopital Saint Louis | Paris | |
France | CHU Bordeaux - Hopital Haut-Leveque - Centre François Magendie | Pessac | |
France | HCL Centre Hospitalier Lyon Sud | Pierre-Bénite | |
France | Institut de cancérologie Strasbourg Europe (ICANS) | Strasbourg | Grand Est |
France | IUCT-Oncopole | Toulouse | Haure-Garrone |
Germany | Universitaetsklinikum Carl Gustav Carus Dresden | Dresden | |
Germany | Universitaetsklinikum Jena | Jena | |
Germany | Universitaetsklinikum Leipzig | Leipzig | |
Germany | Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz | Mainz | |
Germany | Universitaetsklinikum Muenster | Münster | |
Germany | Universitatsklinikum Regensburg | Regensburg | |
Greece | University Hospital of West Attica - Attikon - Hematology Division | Athens | |
Greece | General Hospital of Thessaloniki G. Papanikolaou - Hematology Department, BMT Unit | Exochí | Thessaloniki |
Greece | University General Hospital of Patras | Patras | |
Israel | Rambam Health Care Campus | Haifa | |
Israel | Hadassah Medical Center Ein Karem | Jerusalem | |
Israel | Chaim Sheba Medical Center | Ramat Gan | |
Israel | Tel Aviv Sourasky Medical Center | Tel Aviv | |
Italy | ASST degli Spedali Civili di Brescia | Brescia | |
Italy | Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano | Milano | |
Italy | IRCCS Ospedale San Raffaele | Milano | |
Italy | ASST di Monza-Ospedale San Gerardo | Monza | |
Italy | Fondazione Monza e Brianza per il Bambino e la sua Mamma | Monza | |
Italy | Fondazione IRCCS Policlinico San Matteo | Pavia | |
Italy | Fondazione IRCCS Policlinico San Matteo | Pavia | |
Italy | Fondazione Policlinica Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore | Roma | |
Italy | AOU Citta della Salute e della Scienza di Torino - Ospedale Regina Margherita | Torino | |
Italy | Citta della Salute e della Scienza di Torino - Ospedale le Molinette | Torino | |
Korea, Republic of | Pusan National University Hospital | Busan | |
Korea, Republic of | Korea University Anam Hospital | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital | Seoul | |
Poland | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach - Klinika Transplantacji Szpiku i Onkohematologii | Gliwice | |
Portugal | Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa) | Lisboa | |
Portugal | Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE | Porto | |
Singapore | KK Women's and Children hospital | Singapore | |
Singapore | National University Hospital | Singapore | |
Singapore | Singapore General Hospital | Singapore | |
Spain | Hospital Clinic Barcelona | Barcelona | |
Spain | Hospital Universitario Vall d'Hebron | Barcelona | |
Spain | Hospital Universitario Donostia | Donostia | |
Spain | Complejo Hospitalario Universitario de Granada - Hospital Universitario Virgen de las Nieves | Granada | |
Spain | Hospital General Universitario Gregorio Maranon | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario Ramon y Cajal | Madrid | |
Spain | Hospital Universitario Puerta de Hierro | Majadahonda | |
Spain | Hospital Clinico Universitario de Salamanca | Salamanca | |
Spain | Hospital Universitario Marquis de Valdecilla | Santander | |
Spain | Hospital Universitario Virgen del Rocio | Sevilla | Seville |
Spain | Hospital Clinico Universitario de Valencia | Valencia | |
Spain | Hospital Universitari i Politecnic La Fe | Valencia | |
Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | National Taiwan University Hospital | Taipei | |
United Kingdom | Bristol Royal Hospital for Children | Bristol | |
United Kingdom | University Hospital of Wales | Cardiff | |
United Kingdom | Queen Elizabeth University Hospital | Glasgow | |
United Kingdom | Hammersmith Hospital | London | |
United Kingdom | King's College Hospital NHS Foundation Trust | London | |
United Kingdom | Royal Marsden Foundation Trust | London | |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University | Atlanta | Georgia |
United States | Northside Hospital | Atlanta | Georgia |
United States | Johns Hopkins Kimmel Cancer Center | Baltimore | Maryland |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | University of Alabama at Birmingham - Children's of Alabama | Birmingham | Alabama |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | University of Virginia Medical Center | Charlottesville | Virginia |
United States | The University of Chicago Medical Center (UCMC) | Chicago | Illinois |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | University Hospitals Cleveland Medical Center | Cleveland | Ohio |
United States | The Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | Barbara Ann Karmanos Cancer Institute | Detroit | Michigan |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | City of Hope | Duarte | California |
United States | University of Florida (UF) | Gainesville | Florida |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Franciscan Health Indianapolis | Indianapolis | Indiana |
United States | Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis | Indiana |
United States | Mayo Clinic - Jacksonville | Jacksonville | Florida |
United States | University of California, Los Angeles (UCLA) - Medical Center | Los Angeles | California |
United States | University of Southern California Norris Comprehensive Cancer Center | Los Angeles | California |
United States | The Cleveland Clinic Foundation | Lyndhurst | Ohio |
United States | University of Wisconsin - Carbone Cancer Center | Madison | Wisconsin |
United States | University of Miami | Miami | Florida |
United States | Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | Tulane University Medical Center | New Orleans | Louisiana |
United States | Weill Medical College of Cornell University | New York | New York |
United States | University of Oklahoma - Health Sciences Center | Oklahoma City | Oklahoma |
United States | AdventHealth Orlando | Orlando | Florida |
United States | University of Pittsburgh Medical Center - Hillman Cancer Center | Pittsburgh | Pennsylvania |
United States | Oregon Health & Science University | Portland | Oregon |
United States | Mayo Clinic - Rochester | Rochester | Minnesota |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Intermountain Healthcare | Salt Lake City | Utah |
United States | University of Utah | Salt Lake City | Utah |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
United States | Stanford Cancer Center | Stanford | California |
United States | Stony Brook University Medical Center | Stony Brook | New York |
United States | Moffitt | Tampa | Florida |
United States | Children's National Medical Center | Washington | District of Columbia |
United States | Wake Forest | Winston-Salem | North Carolina |
United States | University of Massachusetts Memorial Medical Center | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Syndax Pharmaceuticals |
United States, Australia, Belgium, Canada, France, Germany, Greece, Israel, Italy, Korea, Republic of, Poland, Portugal, Singapore, Spain, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate in the First 6 Cycles | The overall response rate will be assessed by the number of participants with objective response by Cycle 7 (28-day cycles), Day 1, with responses defined by the 2014 NIH consensus criteria. | Up to Day 169 | |
Secondary | Number of Participants with a Clinically Significant Improvement in Normalized Score on the Modified Lee Symptom Scale | Approximately 30 months | ||
Secondary | Duration of Response | Duration of response is defined as the time from initial partial response or complete response until documented progression of cGVHD, start of new therapy, or death for any reason. | Approximately 30 months | |
Secondary | Sustained Response Rate | Sustained response rate is defined as the number of participants with objective response lasting for at least 20 weeks (140 days) from the time of initial response. Responses by organ system will be assessed based on the 2014 NIH Consensus Development Project on Clinical Trials in cGVHD. | Approximately 30 months | |
Secondary | Organ-specific Response Rate | Organ-specific response is defined as the number of participants with objective response for the nine individual organs based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal [GI], lower GI, liver, lungs and joints and fascia). | Approximately 30 months | |
Secondary | Joints and Fascia Response Rate Based on Refined NIH Response Algorithm for cGVHD | Approximately 30 months | ||
Secondary | Percent Reductions in Average Daily Doses (or Equivalent) of Corticosteroid | Approximately 30 months | ||
Secondary | Number of Participants who Discontinue Corticosteroid Use | Approximately 30 months | ||
Secondary | Percent Reductions in Average Daily Doses (or Equivalent) of Calcineurin Inhibitors (CNI) | Approximately 30 months | ||
Secondary | Number of Participants who Discontinue CNIs | Approximately 30 months | ||
Secondary | Change from Baseline in Circulating Monocyte Levels | Baseline, approximately 30 months | ||
Secondary | Number of Participants with Anti-Drug Antibody | Approximately 30 months | ||
Secondary | Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of Last Measurable Concentration (AUC0-t) | Approximately 12 months | ||
Secondary | AUC from Time 0 to Infinity (AUC0-inf) | Approximately 12 months | ||
Secondary | Observed Maximum Plasma Concentration (Cmax) | Approximately 12 months | ||
Secondary | Time to Observed Maximum Plasma Concentration (Tmax) | Approximately 12 months | ||
Secondary | Number of Participants with Treatment-emergent Adverse Events | Approximately 30 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04189432 -
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Terminated |
NCT03557749 -
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
|
||
Completed |
NCT05121142 -
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
|
Phase 1 | |
Recruiting |
NCT04202835 -
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
|
Phase 2 | |
Terminated |
NCT03640481 -
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
|
Phase 2 | |
Completed |
NCT01036958 -
Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease
|
||
Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
Active, not recruiting |
NCT03604692 -
A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD
|
Phase 1/Phase 2 | |
Recruiting |
NCT05355675 -
The Association of Microbiota Composition With cGVHD After Allo-HSCT
|
||
Terminated |
NCT04200365 -
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
Not yet recruiting |
NCT06263478 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
|
Phase 3 | |
Not yet recruiting |
NCT06388564 -
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Terminated |
NCT02123966 -
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
|
Phase 2 | |
Recruiting |
NCT05692713 -
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
|
||
Terminated |
NCT04446182 -
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
|
Phase 2 | |
Active, not recruiting |
NCT05305989 -
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
|
Phase 2 | |
Active, not recruiting |
NCT02340676 -
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
|
Phase 2 | |
Completed |
NCT04540133 -
Dexamethasone Solution and Dexamethasone in Mucolox™
|
Phase 2 | |
Not yet recruiting |
NCT03190733 -
A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT
|
Phase 4 | |
Active, not recruiting |
NCT04716075 -
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
|
Phase 2 |